Sign In

henry copeland:

ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’ – Endpoints News

Us­ing the es­ke­t­a­mine list price of $295 per 28 mg in­tranasal de­vice, the treat­ment’s use re­sults in an in­cre­men­tal cost-​effectiveness ra­tio of ap­prox­i­mately $198,000 per QALY com­pared to no ad­di­tional treat­ment, ex­ceed­ing the com­monly cited cost-​effectiveness thresh­olds of be­tween $50,000-​$150,000 per QALY. Mean­while, es­ke­t­a­mine is es­ti­mated to cost ap­prox­i­mately $2.6 mil­lion per life year gained, ICER found. Es­ke­t­a­mine’s ap­proval was also meant to en­hance ac­cess to treat­ment — since ke­t­a­mine is not cov­ered by health in­sur­ers — al­though there is a con­cern that there may still be high out-​of-pocket ex­penses through de­ductibles or non-​coverage poli­cies. In­deed, “the place for es­ke­t­a­mine may de­pend on the com­par­a­tive ben­e­fits be­tween es­ke­t­a­mine and other avail­able treat­ments, such as ke­t­a­mine. Un­for­tu­nately, such in­for­ma­tion is not avail­able at this time,” ICER said.
- endpts.com
medicalindustrialcomplex antidepressants
FAQ | Blog | DMCA
© 2025 Pressflex LLC